Italia markets close in 1 hour 48 minutes

Valneva SE (AYJ.DE)

XETRA - XETRA Prezzo differito. Valuta in EUR.
Aggiungi a watchlist
5,30-0,04 (-0,79%)
Al 02:13PM CEST. Mercato aperto.
Schermo intero
Chiusura precedente5,34
Aperto5,25
Denaro5,28 x N/D
Lettera5,31 x N/D
Min-Max giorno5,25 - 5,30
Intervallo di 52 settimane3,98 - 7,79
Volume3.474
Media Volume4.083
CapitalizzazioneN/D
Beta (5 anni mensile)N/D
Rapporto PE (ttm)N/D
EPS (ttm)N/D
Prossima data utiliN/D
Rendimento e dividendo (futuro)N/D (N/D)
Data ex dividendoN/D
Stima target 1AN/D
  • GlobeNewswire

    Valneva Announces New IXIARO® Supply Contract with the U.S. Government Worth a Minimum of $32 Million

    Saint Herblain (France), September 25, 2023 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced the signing of a new $32 million contract with the United States (U.S.) Department of Defense (DoD) for the supply of its Japanese encephalitis (JE) vaccine, IXIARO®. Under this new one-year contract, the DoD will buy a minimum of $32 million worth of IXIARO® vaccines and has the possibility to purchase additional doses during the coming twelve months. Delive

  • GlobeNewswire

    Valneva Reports Half Year 2023 Financial Results and Provides Corporate Updates

    Product sales more than doubled in the first half of 2023 to €69.7 million compared to €33.3 million in the first half of 2022 Driven by IXIARO® and DUKORAL® sales, both of which benefited from a continued recovery of the travel industry as well as from price increasesBringing total revenues to €73.7 million in the first half of 2023 Strong cash position of €204.4 million as at June 30, 2023 Excludes up to an additional $100 million made available as part of a recent upsized financing arrangemen

  • GlobeNewswire

    Valneva and Pfizer Report Positive Pediatric and Adolescent Phase 2 Booster Results for Lyme Disease Vaccine Candidate

    Strong immune response shown in both children and adolescents one month after booster dose (month 19) in VLA15-221 studyPreviously observed high anamnestic antibody response in adults confirmedVLA15 well-tolerated in all age groups following booster dose Saint-Herblain (France) & New York, September 7, 2023 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) and Pfizer Inc. (NYSE: PFE) announced today positive pediatric and adolescent immunogenicity and safety data for their Lyme disease vaccine ca